Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

1719 - Phase 1b/2 Study (SCORES) Assessing Safety, Tolerability, and Preliminary Anti-tumor Activity of Durvalumab Plus AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Squamous Cell Carcinoma of the Head and Neck (SCCHN)


11 Sep 2017


Immunotherapy of cancer


Ezra Cohen


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


E.E. Cohen1, D.S. Hong2, T. Wise Draper3, W. Nassib William4, D. Schrijvers5, R. Mesia Nin6, M.L. Scott7, P. Lyne8, G. Mugundu7, P. McCoon8, C.E. Cook7, M.M. Mehta7, U. Keilholz9

Author affiliations

  • 1 Medicine, University of California, San Diego Moores Cancer Center, 92093 - La Jolla/US
  • 2 Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 77035 - Houston/US
  • 3 Division Of Hematology-oncology, Department of Internal Medicine, Cincinnati/US
  • 4 Department Of Thoracic/head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston/US
  • 5 Department Of Medical Oncology, Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim, Antwerp/BE
  • 6 Servicio De Oncologia Medica, ICO L’Hospitalet, Barcelona/ES
  • 7 Early Clinical Development, AstraZeneca Pharmaceuticals, Waltham/US
  • 8 Imed Oncology, AstraZeneca Pharmaceuticals, Waltham/US
  • 9 -, Charite Comprehensive Cancer Center, 10117 - Berlin/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1719


Anti-tumor activity of durvalumab (D), a programmed death ligand (PDL1) blocking antibody, may be enhanced by overcoming intratumoral immune suppression. The selective Generation 2.5 antisense oligonucleotide STAT3 inhibitor AZD9150 (STATi), a small molecule CXCR2 inhibitor AZD5069 (CX2i), and CTLA4 inhibitor tremelimumab (T) are in evaluation.


Part A, dose escalation in solid tumors, evaluated STATi + (D or D+T) and CX2i + (D or D+T) for safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose. Part B, dose expansion in SCCHN, tested STATi (3 mg/kg)+D and CX2i (40 mg BID)+D in PDL1 pretreated/naive pts and as monotherapy for Objective Response Rate (ORR) and Disease Control Rate (DCR).


Part A showed STATi+D and CX2i+D as safe and tolerable combinations with confirmed partial responses (cPR) in multiple tumor types and 2 confirmed complete responses (cCR) in breast and prostate cancer (>64 weeks [wks] on treatment). STATi+DT had a cPR in sarcoma at 12 wks. In Part B (STATi+D reported here), the PDL1 naive arm had 25% ORR (4 cPR, 1 unconfirmed PR (uPR); 3 Human Papilloma Virus negative and 2 unknown), 45% DCR (9/20) was observed at 12 wks, and 30% of pts (6/20) remain on treatment at 25 wks. One cPR pt is unconfirmed CR at data cut off. In the PDL1 pretreated arm, 1 pt had complete metabolic response and 1 pt had uPR; 20% DCR (3/15) was observed at 12 wks. Safety and tolerability were confirmed for STATi+D in SCCHN pts, with manageable and reversible adverse events of thrombocytopenia and liver enzyme increases (for each, Grade 3/4 in 3.4% of 58 pts dosed); 2 STATi+D related discontinuations occurred.


Initial ORR and DCR data suggest enhanced antitumor activity results from combining a PDL1 antagonist (D) with an agent targeting immunosuppression in the tumor microenviornment (STATi) compared to PDL1 monotherapy. The combination may prove to provide a tolerable and effective option for patients with recurrent/metastatic SCCHN in the naive and PDL1-pretreated setting and other solid tumor types being studied.

Clinical trial identification


Legal entity responsible for the study

AstraZeneca PLC




E.E. Cohen: Consulted for AstraZeneca, Bristol-Myers Squibb, Human Longevity, Merck, Merck Serrano, and Pfizer. Received expenses for travel or accommodation from AstraZeneca, Merck, and Pfizer. Holds stock in Human Longevity, Inc. D.S. Hong: Received grants from Bayer, Lilly, Genentech, LOXO, Pfizer, Amgen, Mirati, Ignyta, Merck, Daichi-Sanko, and Eisai. Travel expenses were provided by MiRNA and LOXO. Consulted for Bayer, Baxter, and Guidepoint Global. He founded Oncoresponse. T. Wise Draper: Received funding for investigator-initiated studies from Bristol-Myers Squibb and Merck. D. Schrijvers: Participated in studies sponsored by Cougar, Janssen, and Bayer. Served on the advisory board of Janssen and Bayer Belgium. Spoken at events organized by Janssen and Bayer Belgium. R. Mesia Nin: Served an advisory role for AstraZeneca, Merck SL, Bayer, and Bristol. Received conference honoraria from Bristol and Merck SL. M.L. Scott, P. Lyne, P. McCoon, C.E. Cook: Employee of, and owns stock in, AstraZeneca. G. Mugundu: Employee of AstraZeneca and owns stock in AstraZeneca and Pfizer. M.M. Mehta: Employed by AstraZeneca. U. Keilholz: Received speaker honoraria, and served on advisory boards, for AstraZeneca, Merck, MSD, Pfizer, Novartis, and Innate. Participates in research sponsored by AstraZeneca and Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.